A public company, headquartered in California, US , the company was founded in the year of 1980.
It has a glorious history of existence in the are of pharmaceuticals and chemicals. Robert A. Bradway is the CEO of the company. It’s a American origin, multinational company, specialized in the area of Biopharmaceuticals and Neurology.
Billion of patients, undergoing cancer chemotherapy, survive depending on Neulasta, Neupogen. The name AMGEN came from Applied Molecular Genetics, and became the official name of the company in the year 1983. In the history of its existence the company has made atleast 5 major corporate acquisitions. In 2010 the company got FDA approval for a number of its product followed by successful clinical trials. In 2012 it acquired KAI pharmaceuticals followed by the acquisition of Onyx Pharmaceutical Inc. in the year of 2013. Amgen has an expanded list of 12 approved drugs or biological formulations for atleast 17 conditions. The company came to the headlines many times previously for fraudulent marketing activities. Still its heading strong towards better tomorrow, delivering high performance to ensure people live longer and better.
Its product portfolio includes, Enbrel, Epogen, Prolia, Kineret, Stemgen etc.